Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Indian CLL and MCL patients
NCT04930536Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), sponsored by AstraZeneca. Primary endpoints: Adverse Events of Special Interest at Day 198 and Second Primary Malignancies at Day 198. Started Jul 2021; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04930536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930536.